Form D · Biotechnology
ArmaGen, Inc.
Calabasas, CA · CIK 0001562829
Offering snapshot reported Mar 2, 2018 · SEC filing
- Reported sold
- $10M Offering amount: $10M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 23, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 2, 2018 | Initial | $9,999,999 | No comparison | 3 | SEC filing |
| Nov 27, 2012 | Initial | $8,492,899 | No comparison | 4 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-306863
Source: Form D, filed Mar 2, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ruben Boado | Executive |
| Martin Heidecker | Director |
| William Pardridge | Director |
| Jayson Punwani | Director |
| Mathias Schmidt | Director, Executive |
| Stuart Swiedler | Director |
| Arthur Tzianabos | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
26679 Agoura Road Suite 100
Calabasas, CA, 91302
Calabasas, CA, 91302